Atossa Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Atossa Therapeutics, Inc. will hold a Special Meeting on January 20, 2026, to seek stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price rule and avoid delisting.
NASDAQ
Atossa Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on May 8, 2025, outlining proposals for director elections, auditor ratification, executive compensation, and vote frequency.
NASDAQ
DEF 14A: Atossa Therapeutics Seeks Stockholder Approval for Share Increase and Incentive Plan Amendment
Atossa Therapeutics is holding its annual meeting on June 27, 2024, to vote on key proposals including increasing authorized shares and amending the stock incentive plan.